Senior Director, Analytical Development South San Francisco

Marea Therapeutics is a clinical-stage biotechnology company based in South San Francisco with a growing pipeline of first-in-class therapies to address genetically validated cardioendocrine disease targets. Our therapies have the potential to complement existing therapies and serve as transformative treatment options for significant patient populations living with cardioendocrine diseases.

Incubated by Third Rock Ventures, Marea completed a Series B financing in June 2024 and is well funded by a syndicate of leading life science investors including Sofinnova, Forbion, Xontogeny/ Perceptive Advisors, venBio, Omega Funds, Surveyor, Alpha Wave and Third Rock Ventures.

The company’s lead program, MAR
001, is a monoclonal antibody targeting ANGPTL4, a genetically validated target with potential to address the subset of patients at the highest risk of adverse cardiovascular events, despite current standard of care therapies. MAR
001 is rapidly progressing through Phase 2b clinical development. Our second clinical asset, MAR
002, is a monoclonal antibody targeting excess growth hormone produced by the pituitary gland in the rare hormonal disorder, acromegaly. MAR
002 has potential to become best-in-disease and is rapidly progressing through Phase 1 clinical development. We also have a third asset that is rapidly advancing through research discovery, with DC nomination expected next year.

At Marea, we believe in the power of collaboration and the importance of leading by example. We are a tight-knit team that values the contributions of every member, from interns to senior leaders. Our environment is dynamic, with each day presenting new challenges and opportunities for growth. Every role is “Hands‑On”, and the successful candidate will be able to work alongside team members, regardless of level, to understand challenges and drive results.

The Senior Director of Analytical Development will be both the strategic head and technical driver of analytical development across Marea’s pipeline. This individual will set the vision for analytical sciences while also remaining engaged in the detailed design, execution, and troubleshooting of methods. This is a key role in the Technical Operations team as we aggressively advance the first program towards late‑stage development and our second program into early‑stage clinical development.

This role will initially report to the CTO. The successful candidate will be a working leader: equally comfortable shaping analytical strategy suitable for major submissions, presenting to authorities, and personally reviewing data packages or troubleshooting methods with the team and partners. The successful candidate will have strong technical background in developing, qualifying and transferring necessary in‑process, release and characterization methods to support development of all monoclonal antibody programs  candidate will work closely with other members of the technical operations team including process development, manufacturing, QC and QA, and CMC regulatory as well as cross‑functionally with research and clinical team to support the larger program goals.

Ideal candidate will offer a mix of strong technical skills in monoclonal antibody method development, hands‑on laboratory development experience, experience working with CDMOs and CTLs and ability to develop strong written technical data packages that are phase appropriate and of high quality expected in regulatory submissions. Candidate needs to have demonstrated experience or minimally basic familiarity in various physicochemical methods (chromatographic, electrophoretic, peptide mapping), biochemical assays, functional assays, impurity and residual testing, stability and degradation studies to support the overall product release, process control, product characterization, process improvements, comparability assessments and regulatory submissions.

Solid understanding of the necessary ICH and USP regulations and experience supporting regulatory submissions at various development stages is critical. We expect this candidate to be hands on and be adaptable to the evolving needs in a start‑up environment.